BACKGROUND As a foundation for quality improvement, assessing clinical outcomes across hospitals requires
M
ortality from cardiovascular disease has decreased dramatically over the past few decades (1), in part because of improvements in acute myocardial infarction (AMI) management (2) . In-hospital mortality has decreased from 29% in 1969 (3) to <7% today (4, 5) . However, more than 100,000 people continue to die after AMIs in the United States each year (1), and in-hospital mortality varies substantially across hospitals (5), suggesting an opportunity for improvement. Adjustment for the variation in patient risk across hospitals is essential to enable a more accurate assessment of each hospital's performance and opportunity to improve.
Although many risk models of in-hospital mortality have been developed for patients with AMI (6-13), few have included a representative sample from routine clinical care. In 2011, a simple, validated risk model was developed using data from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-GWTG (Get With the Guidelines), which included patients from more than 300 hospitals (14) . Since that time, ACTION Registry-GWTG collection has been expanded to identify patients presenting after cardiac arrest at the time of AMI presentation. Being able to adjust for cardiac arrest is critical because it is a well-documented predictor of mortality (10, 15) . Moreover, continued improvement in AMI care mandates periodic updates to the risk models so that hospitals can assess their quality as contemporary care continues to evolve.
To update the existing ACTION-GWTG mortality risk model, we rebuilt the ACTION Registry-GWTG in-hospital mortality risk model using data from January 2012 through December 2013.
We also sought to build a parsimonious risk score that could be used prospectively for risk stratification.
These tools are designed to be used to further support quality improvement and to aid in clinical management during an AMI. Briefly, participating hospitals collect data through retrospective chart review using standardized data McNamara et al.
METHODS
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A U G U S T 9 , 2 0 1 6 : 6 2 6 -3 5 AMI Risk Model for In-Hospital Mortality collection tools that do not require direct patient contact. Collected data include patient demographics; presenting features; pre-hospital, in-hospital, and hospital discharge therapy; timing of treatments; laboratory tests; procedures; and in-hospital outcomes.
On the basis of individual site determinations, this registry was either approved by an Institutional Review Board or considered a quality assurance effort and thus not subject to Institutional Review Board approval (16) . The National Cardiovascular Data Registry also has a data quality program, including data abstraction training, data quality thresholds for inclusion, site data quality feedback reports, independent auditing, and data validation (17) . Data auditing has demonstrated accurate representation with agreement with chart review of 93% (18) . Baseline creatinine clearance was estimated using the Cockcroft-Gault formula (19) . Baseline troponin ratio was defined as the baseline troponin value divided by the local laboratory-specific upper limit of normal. This approach accounted for the different local laboratory troponin assays using different reference ranges and has been used previously to investigate the association of maximum troponin ratio with outcomes (20) . Electrocardiograms at presentation were interpreted locally. Values are mean AE SD, n (%), or median (interquartile range).
CABG ¼ coronary artery bypass graft surgery; ECG ¼ electrocardiography; HF ¼ heart failure; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure; STEMI ¼ ST-segment elevation myocardial infarction. Values are %.
NSTEMI ¼ non-ST-segment elevation myocardial infarction; other abbreviations as in Table 1 .
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were identified from the list of all ACTION Registry-GWTG data elements that would be known at the time of initial hospital presentation (variables in Table 1 ). 
RESULTS
In terms of baseline characteristics for the derivation (n ¼ 145,952) and validation (n ¼ 97,288) cohorts (Table 1) , no important differences were observed between the 2 groups. Selected in-hospital management is shown in Table 2 .
The bivariate relationships between patient characteristics and in-hospital mortality are shown for continuous variables in Table 3 and for categorical variables in Table 4 . In multivariate analysis (Table 5) , 9 variables were independently associated with in-hospital mortality: age; presenting heart rate and systolic blood pressure; presentation after cardiac arrest, in cardiogenic shock, in heart failure, and with STEMI; creatinine clearance; and troponin ratio.
The final ACTION Registry-GWTG in-hospital mortality model had high discrimination in both the derivation and validation populations, with a C statistic of 0.88 for both. There was also excellent calibration of the model in the validation cohort Values are mean AE SD or median (interquartile range).
SBP ¼ systolic blood pressure. Abbreviations as in Table 1 .
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The Observed Rate
Expected Rate
Expected in-hospital mortality rate was plotted against observed in-hospital mortality rate for each decile of patient risk.
Given the inherent differences in the populations and goals of these models, the present ACTION Registry-GWTG model was not tested against these prior and previous models include the use of creatinine clearance rather than serum creatinine level (which was less predictive) and the separation of heart failure and cardiogenic shock at the time of presentation, which were both independently associated with in-hospital mortality.
Cardiac arrest has been shown to be an important predictor of AMI mortality in multiple previous Furthermore, these C statistics align well with other clinical risk models in patients with AMI (8, 10, 31, 32 Tables 1 and 2 .
Finally, the model has been validated using only ACTION Registry-GWTG data; it has not been validated on an external dataset. 
CONCLUSIONS
